Appears in Networks 1

Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system v1.0.0

This document contains the curation of the review article Nicotinic receptors: allosteric transitions and therapeutic targets in the nervous system by Taly et al. 2009

Provenance

PubMed:19721446

Both initiatives were successful: new compounds — A-366833 and ABT-894 — with improved α4β2 selectivity and a broad spectrum of analgesic efficacy without adverse effects were identified236. ABT-894 was chosen to go into Phase ii clinical trials but the results were disappointing, and the development of this compound for neuropathic pain has been discontinued. The compound remains in clinical trials for ADHD.

Annotations 1

Text Location
Review

About

BEL Commons is developed and maintained in an academic capacity by Charles Tapley Hoyt and Daniel Domingo-Fernández at the Fraunhofer SCAI Department of Bioinformatics with support from the IMI project, AETIONOMY. It is built on top of PyBEL, an open source project. Please feel free to contact us here to give us feedback or report any issues. Also, see our Publishing Notes and Data Protection information.

If you find BEL Commons useful in your work, please consider citing: Hoyt, C. T., Domingo-Fernández, D., & Hofmann-Apitius, M. (2018). BEL Commons: an environment for exploration and analysis of networks encoded in Biological Expression Language. Database, 2018(3), 1–11.